Altogether, our data highlight that NRG1 may exert both pro- and anti-proliferative effects on HER2+ breast cancer cellular models, and may reduce the efficacy of anti-HER2 agents, whereas NRG4 consistently boosts the anti-proliferative effects of anti-HER2 agents (Figure 7). The gene discussed is ERBB2; the disease is breast carcinoma.